info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Agnosia Treatment Market: By Diagnosis (CT, MRI) Causes (Alzheimer's Disease, Pick's Disease, Melas, Balint's Syndrome) Type (Auditory Agnosia, Gustatory Agnosia, Olfactory Agnosia, Tactile Agnosia, Visual Agnosia) Treatment - Forecast till 2032


ID: MRFR/Pharma/3610-HCR | 80 Pages | Author: Rahul Gotadki| October 2024

Agnosia Treatment Market Overview


Agnosia Treatment Market Size was valued at USD 0.08 Billion in 2023. The Global Agnosia Treatment industry is projected to grow from USD 0.12 Billion in 2024 to USD 0.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.12% during the forecast period (2024 - 2032).Agnosia is a rare neurological condition in which an individual may face difficulty to recognize a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.


Agnosia Treatment Market


People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.


In June 2024, medical treatment for visual agnosia usually addresses the underlying cause first, i.e., infection or tumors, with medications and/or surgery. Rehabilitation strategies include making use of other senses as compensation and setting up patterns of behavior to assist in recognition. Therapy and support can help individuals adapt to long-term or permanent conditions.


In June 2024: Targeted exercises and compensatory strategies such as lip-reading or association are among the approaches for managing auditory agnosia, which impairs sound recognition despite having normal hearing.


In June 2024, GoodTherapy highlights the use of occupational and speech therapy in treating agnosia, focusing on adaptive strategies like organizational techniques utilizing other senses to make sense of sensory information.


In June 2024, Flint Rehab emphasizes the importance of neuroplasticity in rehabilitating patients with agnosias. To rewire their brains, enhancing sensory processing through repeated practice-based exercises and activities tailored to individual deficits are involved in intensive, task-specific practice.


Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.


Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.


The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome.  Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).


Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia.  According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2032 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.


There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.


Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.


Agnosia Treatment Market Segmentation


The agnosia treatment market is segmented on the basis of diagnosis, causes, type, and treatment.


On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.


On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.


On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia


On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole


Agnosia Treatment Market Regional Analysis


The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.


North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.


Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.


Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. 


Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.


Key Players in the Agnosia Treatment Market



  • B. Braun Melsungen (Germany)

  • Pfizer Inc. (U.S.)

  • Lupin ltd. (India)

  • Fujifilm Holdings (Japan)

  • GE Healthcare (U.S.) 

  • Siemens Healthcare(U.S.)

  • Philips Healthcare (U.S.)

  • F. Hoffmann-La Roche AG (Switzerland)

  • Aurobindo Pharma Ltd (India)

  • Sandoz GmBH (Austria)

  • Stellar- Bio Labs (India)

  • Fresenius Kabi Ipsum SRL (Italy)

  • Zhuhai United Laboratories Co Ltd (China)

  • Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China)

  • IPCA Labs ltd. (India)


Intended Audience



  • Agnosia treatment Suppliers

  • Agnosia treatment Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities

Report Attribute/Metric Details
Market Size USD 0.34 Billion by 2032
CAGR 4.12% (2024-2032)
Base Year   2023
Forecast Period   2024-2032
Historical Data   2022
Forecast Units   Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Types, end user, Region
Geographies Covered America, Europe, Asia Pacific, Middle East and Africa
Key Vendors B. Braun Melsungen (Germany), Pfizer Inc. (U.S.), Lupin ltd. (India),Fujifilm Holdings (Japan), GE Healthcare (U.S.),Siemens Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG (Switzerland),Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar- Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy),Zhuhai United Laboratories Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China),IPCA Labs ltd. (India)


Frequently Asked Questions (FAQ) :

agnosia treatment market is projected to grow at a 4.12% CAGR between 2024-2032.

North America is projected to dominate the agnosia treatment market.

Different types of agnosia include visual agnosia, tactile agnosia, olfactory agnosia, gustatory agnosia, auditory agnosia, among others.

Some common causes of agnosia include Balint’s syndrome, Pick’s disease, and Alzheimer’s.

Eminent players profiled in the agnosia treatment market include IPCA Labs ltd. (India), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), Zhuhai United Laboratories Co Ltd (China), Fresenius Kabi Ipsum SRL (Italy), Stellar- Bio Labs (India), Sandoz GmBH (Austria), Aurobindo Pharma Ltd (India), F. Hoffmann-La Roche AG (Switzerland) , Philips Healthcare (U.S.), GE Healthcare (U.S.), Fujifilm Holdings (Japan), Lupin ltd. (India), Pfizer Inc. (U.S.), and B. Braun Melsungen (Germany).

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.